盛禾生物-B（02898）8月4日晚间公告，根据香港联合交易所有限公司证券上市规则第13.09条及《证券及期货条例》相关内幕消息条文，公司已委任郑郑风险管理咨询服务有限公司为独立内部监控顾问，开展独立内部监控检讨。\n\n该检讨将分三阶段进行：(i) 初步评估——了解集团现有内部监控框架；(ii) 深入检讨——识别监控缺陷并提出补救措施；(iii) 后续检讨——评估补救措施成效。覆盖范围包括财务汇报、采购、销售、现金管理、预付款项管理、研发、外包、合约管理、上市规则合规及其他重大营运和管治流程。\n\n截至公告日，独立内部监控检讨仍在进行中。公司表示，将适时披露检讨进展及任何重大发现。\n\n公司股票自2026年4月1日09:00起在联交所暂停买卖，原因系延迟刊发2025年年度业绩。停牌状态将维持至相关业绩发布完毕。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.